The hepatitis B vaccine was first introduced into the routine immunization program in Henan Province, China in 1992. In 2012, a survey was conducted to evaluate the protective effects of hepatitis B vaccination for the populations born during the preceding 15 years. A multistage stratified random cluster sampling method was used to collect samples. The participants were interviewed and relevant information was obtained for the population aged 1 to 14 years using a standardized questionnaire; a 2- or 3-ml serum sample was taken from each participant to measure hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc). Association and logistic regression analyses were conducted to determine relationships between these parameters. A total of 13,207 residents aged 1 to 14 years residing in 60 villages or communities in Henan, China were surveyed and had their blood collected. Serological analysis revealed that the HBsAg and anti-HBc prevalences were 0.8% and 2.6%, respectively. The HBsAg prevalence among children under 5 years of age was 0.5%, showing a decline of 96% compared to the average national HBsAg prevalence in 1992. Children had a higher likelihood of HBsAg positivity if they had an HBsAg-positive family member (odds ratio (OR) 4.26), no history of vaccination (OR 2.06), were born in a smaller township hospital or at home (OR 1.61), were aged 10-14 years (OR 2.07), or were living in a rural area (OR 2.01). The HBsAg prevalence rate in persons under 15 years of age has dropped significantly in Henan Province after two decades of vaccination. Thus millions of chronic HBV infections have been prevented.
To analyze the effects of one dose of live attenuated hepatitis A vaccine in a developing country. The reported cases of hepatitis A virus (HAV) infection from 2005 to 2018 in Henan province, China, were analyzed. Data of vaccinated children were assessed on the childhood immunization information management system. Questionnaire survey and blood sample collection were randomly conducted in six counties and districts of Henan province to analyze the prevalence of HAV lgG among the population aged 0-70 years. In 2008, Henan province began to expand its program on immunization, and children aged 18 months were given one dose of live attenuated hepatitis A vaccine (HepA-L). From 2005 to 2007, the HAV incidence remained steady at above 5000 cases per year and increased to 7489 in 2007. Since 2008, the HAV incidence decreased cumulatively from 4576 to 237 in 2018, indicating a 94.8% decrease, which was particularly pronounced among adolescents (98.2%). The proportion of hepatitis A cases in patients younger than 10 years continually decreased from 41.6% in 2012 to 3.8% in 2018. The reduction of reported cases older than 40 years was slower than that of children. In 2012, the proportion of hepatitis A cases older than 40 years was 27.6%, and continually increased to 69.2% (164/237) in 2018. The results of serological investigation showed that the 0-1.5-year age group had the lowest anti-HAV IgG prevalence (38.6%), which increased to 75.0% in the 4-6-year age group, covered by this immunization program. The data indicated a large decrease in HAV infections in Henan province from 2008 onward in response to the introduction of a planned immunization program of HepA-L.